Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians
The DOI matches its Crossref record; 370 of the 370 references it cites were found in a registry or an index.
Abstract
Description: This guideline updates the 2008 American College of Physicians (ACP) recommendations on treatment of low bone density and osteoporosis to prevent fractures in men and women. This guideline is endorsed by the American Academy of Family Physicians. Methods: The ACP Clinical Guidelines Committee based these recommendations on a systematic review of randomized controlled trials; systematic reviews; large observational studies (for adverse events); and case reports (for rare events) that were published between 2 January 2005 and 3 June 2011. The review was updated to July 2016 by using a machine-learning method, and a limited update to October 2016 was done. Clinical outcomes evaluated were fractures and adverse events. This guideline focuses on the comparative benefits and risks of short- and long-term pharmacologic treatments for low bone density, including pharmaceutical prescriptions, calcium, vitamin D, and estrogen. Evidence was graded according to the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system. Target Audience and Patient Population: The target audience for this guideline includes all clinicians. The target patient population includes men and women with low bone density and osteoporosis. Recommendation 1: ACP recommends that clinicians offer pharmacologic treatment with alendronate, risedronate, zoledronic acid, or denosumab to reduce the risk for hip and vertebral fractures in women who have known osteoporosis. (Grade: strong recommendation; high-quality evidence). Recommendation 2: ACP recommends that clinicians treat osteoporotic women with pharmacologic therapy for 5 years. (Grade: weak recommendation; low-quality evidence). Recommendation 3: ACP recommends that clinicians offer pharmacologic treatment with bisphosphonates to reduce the risk for vertebral fracture in men who have clinically recognized osteoporosis. (Grade: weak recommendation; low-quality evidence). Recommendation 4: ACP recommends against bone density monitoring during the 5-year pharmacologic treatment period for osteoporosis in women. (Grade: weak recommendation; low-quality evidence). Recommendation 5: ACP recommends against using menopausal estrogen therapy or menopausal estrogen plus progestogen therapy or raloxifene for the treatment of osteoporosis in women. (Grade: strong recommendation; moderate-quality evidence). Recommendation 6: ACP recommends that clinicians should make the decision whether to treat osteopenic women 65 years of age or older who are at a high risk for fracture based on a discussion of patient preferences, fracture risk profile, and benefits, harms, and costs of medications. (Grade: weak recommendation; low-quality evidence).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Affected trial reports were cited in nine effectiveness reviews and clinical guidelines (one published in Scotland, the others in the USA), for stroke,49 fracture prevention50–55 and fall and injury prevention.56”
From An investigation into the impact and implications of published papers from retracted research: systematic search of affected literature (2019) · cites this paper as [55]
In the citing paper
“The updated 2017 American College of Physicians’ guidelines55 (74 citations, October 2018) includes two of the affected trial reports on 2.5 mg daily risedronate13 16 in its overview of the evidence for the use of risedronate from the AHRQ review,54 but does not discuss the specific issue of the lower dose of risedronate.”
From An investigation into the impact and implications of published papers from retracted research: systematic search of affected literature (2019) · cites this paper as [55]
In the citing paper
“Fracture risk approximately doubles with every SD T-score reduction.137,138”
From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [138]
Citations
Cites
9 retracted
Sato, Y., Iwamoto, J., Kanoko, T., & Satoh, K. (2005) · Cerebrovascular Diseases · doi:10.1159/000087203 · Cited by 410
RetractedWimalawansa, S. J. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00029-1 · Cited by 186
RetractedIshida, Y., & Kawai, S. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2004.05.019 · Cited by 132
RetractedSato, Y., Manabe, S., Kuno, H., & Oizumi, K. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.1.64 · Cited by 131
Retracted(2007) · Neurology · doi:10.1212/01.wnl.0000257089.50476.92 · Cited by 90 · cited 5×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialRetractedSato, Y., Kanoko, T., Satoh, K., & Iwamoto, J. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.15.1737 · Cited by 69 · cited 5×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialRetracted(2003) · Neurology · doi:10.1212/01.wnl.0000078892.24356.90 · Cited by 51
RetractedSato, Y., Kuno, H., Kaji, M., Saruwatari, N., & Oizumi, K. (1999) · American Journal of Physical Medicine & Rehabilitation · doi:10.1097/00002060-199909000-00008 · Cited by 37
RetractedAnti-Fracture Efficacy of Risedronic Acid in Men: A Meta-Analysis of Randomized Controlled Trials
Zhong, Z., & Chen, J. (2009) · Clinical Drug Investigation · doi:10.2165/00044011-200929050-00007 · Cited by 30 · cited 5×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialRetractedWriting Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Research works printed but not linked: 25
- Bonnick S, 1998, Bone, 23, S476
- 10.1210/jcem.85.2.6393 · doi:10.1210/jcem.85.2.6393 · Paper page
- 10.1185/030079903125002009 · DOI · Paper page
- McClung M, 1998, Osteoporos Int, 8, 111
- Chao M, 2013, Pak J Med Sci, 29, 1381
- Lippuner K, 2013, Osteoporosis Int, 24, S39
- Palacios S, 2013, Osteoporosis Int, 24, S299
- Papapoulos S, 2013, Osteoporosis Int, 24, S45
- 10.1359/jbmr.2003.18.1.9 · DOI · Paper page
- 10.1210/jcem.85.9.6836 · doi:10.1210/jcem.85.9.6836 · Paper page
- Adachi JD, 1996, J Rheumatol, 23, 995
- Aloia JF, 1985, J Lab Clin Med, 106, 630
- Caniggia A, 1984, Acta Vitaminol Enzymol, 6, 117
- Geusens P, 1986, Bone Miner, 1, 347
- Jensen GF, 1985, Clin Orthop Relat Res, 215
- Menczel J, 1994, Clin Orthop Relat Res, 241
- Orimo H, 1987, Bone Miner, 3, 47
- Muscoso E, 2004, Eur Rev Med Pharmacol Sci, 8, 97
- Migliore A, 2013, Eur Rev Med Pharmacol Sci, 17, 658
- Almăşan HA, 2011, Rom J Morphol Embryol, 52, 1233
- 10.1056/nejmoa011807 · DOI · Paper page
- Krohn K, 2014, Osteoporosis Int, 25, S61, 10.1007/s00198-013-2525-0 · DOI
- 10.1210/jcem.87.3.8325 · doi:10.1210/jcem.87.3.8325 · Paper page
- Zheng S, 2003, Chin Med J (Engl), 116, 1127
- Liu JL, 2004, Chin Med J (Engl), 117, 1029
Cited by
Items 301–400 of 741
Bisphosphonates: Mechanisms of Action and Role in Osteoporosis Therapy
Santora, A. C., & Sharma, A. (2020) · Contemporary Endocrinology · doi:10.1007/978-3-319-69287-6_14 · Cited by 13
Rajfer, R. A., Flores, M., Abraham, A., Garcia, E., Hinojosa, N., Desai, M., Artaza, J. N., & Ferrini, M. G. (2019) · Journal of Osteoporosis · doi:10.1155/2019/1592328 · Cited by 13
“as a treatment for postmenopausal osteoporosis because they have a lower breast cancer risk than that seen with estrogen itself, but the SERMs still carry the risk of developing thromboembolic episodes [35, 36].”
BackgroundTreatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women
Sugiyama, T. (2017) · Annals of Internal Medicine · doi:10.7326/l17-0482 · Cited by 13
Ma, X., Luan, Z., Zhao, Q., Yang, A., & Li, J. (2024) · Biomaterials Research · doi:10.34133/bmr.0058 · Cited by 12
Inflammatory bowel disease and osteoporosis: Common genetic effects, pleiotropy, and causality
Hu, Y., Jin, X.-J., Lei, S., Yu, X., & Bo, L. (2024) · Human Immunology · doi:10.1016/j.humimm.2024.110856 · Cited by 12
The association between dietary mineral intake and bone mineral density: a cross-sectional study
Wei, M., Wei, J., & Huang, S. (2025) · Journal of Health Population and Nutrition · doi:10.1186/s41043-025-01010-1 · Cited by 12
Mori, T., Crandall, C. J., Fujii, T., & Ganz, D. A. (2021) · Archives of Osteoporosis · doi:10.1007/s11657-021-00891-z · Cited by 12
Mandatori, D., Penolazzi, L., Pelusi, L., Lambertini, E., Michelucci, F., Porreca, A., Cerritelli, P., Pipino, C., Iorio, A. D., Bruni, D., et al. (2021) · Nutrients · doi:10.3390/nu13082823 · Cited by 12
“Several studies aiming to develop new pharmacological approaches to treat or delay its progression have been performed [2].”
BackgroundLi, Z., Ye, F., Huang, C., Liu, Q., Huang, M., Chen, B., Peng, Z., Zhu, W., & Ding, B. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.934598 · Cited by 12
The Good and the Bad About the 2017 American College of Physicians Osteoporosis Guidelines
Lagari, V. S., Gavcovich, T. B., & Levis, S. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.11.008 · Cited by 12
Osteoking improves OP rat by enhancing HSP90‑β expression
Sun, Y., Chen, R., Zhu, D., Zhi-qiang, S., Zhao, H., & Lee, W. (2020) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2020.4529 · Cited by 12
Microbial RNAs Pressure Piezo1 to Respond
Matute, J. D., Duan, J., & Blumberg, R. S. (2020) · Cell · doi:10.1016/j.cell.2020.07.015 · Cited by 12
Gu, Z.-J., Yuanyuan, Y., Lingyu, Z., & Chen, C. (2020) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.15598 · Cited by 12
“Studies were eligible if they met the following criteria: (1) having a longitudinal design; (2) including people with osteoporosis or osteopenia (defined by bone mineral density (BMD) assessment using any validated tool according to a clear standard diagnostic criteria or any documented medical or insurance records);…”
MethodOh, H., Yoon, B., Park, J.-W., Jeon, Y. J., Yoo, B., Bak, J. K., Ha, Y., & Lee, Y. (2023) · Gastric Cancer · doi:10.1007/s10120-023-01397-y · Cited by 11
“However, men are less likely than women to be screened for osteoporosis and to receive treatment for osteoporotic fractures, even gastric cancer is more frequent in males [25, 26, 27].”
BackgroundMethodCasabella, A., Paladin, F., Bighin, C., Ottaviani, S., Marelli, C., Ponzano, M., Signori, A., Murdaca, G., Cutolo, M., Molfetta, L., et al. (2024) · Internal and Emergency Medicine · doi:10.1007/s11739-024-03725-1 · Cited by 11
“In turn, inactivation of the RANK/RANKL/OPG signaling pathway reduces bone resorption (i.e. prevents bone loss) and tumor-induced bone destruction [10–12].”
Utilizing surface-enhanced Raman spectroscopy for the adjunctive diagnosis of osteoporosis
Yang, W., Xia, S., Xu, J., Zhu, Y., Li, L., Jiang, C., Ji, H., & Shi, F. (2024) · European journal of medical research · doi:10.1186/s40001-024-02081-2 · Cited by 11
“Currently, diagnosis and clinical efficacy assessment of OP primarily rely on clinical symptoms (such as fragility fractures) and medical imaging findings (including dual-energy X-ray absorptiometry, quantitative computed tomography, and quantitative ultrasound) [6–8].”
BackgroundMohanty, S., Sahu, A., Mukherjee, T., Kispotta, S., Mal, P., Gupta, M., Ghosh, J. K., & Prabhakar, P. K. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-01749-3 · Cited by 11
“Osteoporosis is a global condition characterized by bone mass depletion and re-modification of the bone's structure, leading to higher bone fragility and fracture threat (Dunnewind et al. 2017; Qaseem et al. 2017).”
Quercetin in metabolic diseases: mechanisms, therapeutics, and multidimensional frontiers
Song, Q., Liu, L., Yang, Q., Pan, M., & Zhang, Y. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1800322 · Cited by 11
“While existing treatments, including hormone therapy, antiresorptive agents, and bone-forming medications, can alleviate symptoms to some extent, they are often associated with adverse effects and variable individual responses (95, 96).”
Li, X., Ning, L., Zhao, X., & Wan, S. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28143 · Cited by 11
“It was shown that the only anabolic agent that stimulates bone formation is teriparatide.(19) The limitations of the current osteoporosis treatment options give rise to the need for new therapeutic strategies.”
BackgroundFan, L., Yang, K., Yu, R., Hui, H., & Wu, W. (2022) · Arthritis Research & Therapy · doi:10.1186/s13075-022-02964-x · Cited by 11
Screening and early treatment for osteoporosis: Who are we missing under age 65?
Ishimoto, A. K., & Shah, A. A. (2024) · Maturitas · doi:10.1016/j.maturitas.2024.108044 · Cited by 11
Efficacy Versus Effectiveness: The HORIZON‐Pivotal Fracture Trial and Its Emulation in Claims Data
D’Andrea, E., Schneeweiß, S., Franklin, J. M., Kim, S. C., Glynn, R. J., Lee, S. B., & Wang, S. V. (2024) · Arthritis & Rheumatology · doi:10.1002/art.42968 · Cited by 11
Saha, P. K., Oweis, R. R., Zhang, X., Letuchy, E. M., Eichenberger‐Gilmore, J. M., Burns, T. L., Warren, J. J., Janz, K. F., Torner, J. C., Snetselaar, L. G., et al. (2021) · Bone · doi:10.1016/j.bone.2021.115882 · Cited by 11
Knowledge and Needs of Resident Physicians Regarding Osteoporosis: A Nationwide Survey of Residents
Crandall, C. J., Chen, L., Rodriguez, T. D., Elashoff, D. A., Faubion, S. S., Kling, J. M., Shifren, J. L., Skinner, L. J., & Bauer, D. C. (2021) · JBMR Plus · doi:10.1002/jbm4.10524 · Cited by 11
Braz, R. R. S., Campos, S. L., Wanderley, D., Antonino, G. B., Batista, P. K. A., Guerino, M. R., Rodrigues, F. T. M., Alves, K. F. P., Duarte, J., Silva, D. D. A., et al. (2022) · Biology · doi:10.3390/biology11020266 · Cited by 11
Vasomotor and Related Menopause Symptoms
Stuenkel, C. A. (2018) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000000385 · Cited by 11
Xia, S., Qin, X., Wang, J., & Ren, H. (2023) · Stem Cell Research & Therapy · doi:10.1186/s13287-023-03605-z · Cited by 10
“Raloxifen is a selective estrogen receptor modulator, which can prevent bone loss and reduce the risk of vertebral fracture [22].”
BackgroundOral Cannabidiol Treatment in Two Postmenopausal Women with Osteopenia: A Case Series
Kulpa, J., Harrison, A., Rudolph, L., Eglit, G. M. L., Turcotte, C. L., Bonn‐Miller, M. O., & Peters, E. N. (2023) · Cannabis and Cannabinoid Research · doi:10.1089/can.2023.0060 · Cited by 10
“24 Although some studies have reported elevation of ALT after prolonged CBD dosing, 25 we instead saw a 62.7% (Participant 001, 100 mg CBD) and 42.9% (Participant 002, 300 mg CBD) nonclinically signifi-cant reduction in this liver enzyme across the dosing period, and no noteworthy changes in serum…”
InfluentialCausal association of metformin and osteoporosis: A 2-sample Mendelian randomization study
Wei, Y.-K., Chen, P.-B., Ju, L.-L., & Deng, G.-H. (2023) · Medicine · doi:10.1097/md.0000000000035191 · Cited by 10
“[4,5] However, osteoporosis remains a common orthopedic chronic disease threatening health.”
BackgroundAgostini, F., Alessandro de, S. I. R. E., Sveva, V., Finamore, N., Savina, A., Fisicaro, A., Bernetti, A., Santilli, V., Mangone, M., & Paoloni, M. (2024) · Disability and Rehabilitation · doi:10.1080/09638288.2024.2440142 · Cited by 10
“…exercises such as single leg standing and dynamic low strength exercises such as Tai-chi and progressive strength resistance training for post-menopausal women (GoR B) [26]. while supporting the positive impact of exercise on bone density, several studies warn of potential risks [25,32].”
InfluentialAssociation between sarcopenia index and the risk of second hip fracture in older adults
Yu, L., Liu, F., Zhang, Q., Yan, W., & Zhang, M. (2025) · The journal of nutrition health & aging · doi:10.1016/j.jnha.2025.100532 · Cited by 10
Impaired Bone Mineral Density in Pediatric Patients with Chronic Graft-versus-Host Disease
Buxbaum, N. P., Robinson, C., Sinaii, N., Ling, A. L., Curtis, L. M., Pavletic, S. Z., Baird, K., & Lodish, M. B. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.02.019 · Cited by 10
Li, M., Li, S., Liu, J. F., Cui, X., Zhang, S., Zhou, J., Wang, X., & Yao, Q. (2019) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.36704 · Cited by 10
Burns, R. B., Rosen, H. N., Berry, S. D., & Smetana, G. W. (2018) · Annals of Internal Medicine · doi:10.7326/m18-0950 · Cited by 10
Shen, S., Wang, W., Yang, C., Xu, B., Zeng, L., & Qian, Y. (2018) · Journal of Oral Pathology and Medicine · doi:10.1111/jop.12801 · Cited by 10
Nunes, F. A. P., Farias, M. L. F., Oliveira, F., Neto, L. V., Lima, L. F. C., Paranhos‐Neto, F. D. P., de Mendonça, L. M. C., & Madeira, M. (2021) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000385 · Cited by 10
The hot flush: symptom of menopause or sign of disease?
Baber, R. (2017) · Climacteric · doi:10.1080/13697137.2017.1342346 · Cited by 10
Autorinnen/Autoren, & Collaborators (2025) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2558-5204 · Cited by 10
The role of fat-soluble vitamins on bone metabolism and osteoporosis: a literature review
Li, H., Cao, W., Tao, L., & Zhu, Y. (2025) · Annals of Medicine · doi:10.1080/07853890.2025.2533429 · Cited by 9
“While vitamin D plays a clear role in preventing osteoporosis, numerous studies have concluded that it does not serve as a direct treatment for osteoporosis [34,60,88].”
Osteoporosis management in the United States
Hoggard, T. M., & Jeray, K. J. (2022) · OTA International The Open Access Journal of Orthopaedic Trauma · doi:10.1097/oi9.0000000000000184 · Cited by 9
Lin, H., Lin, R., Hou, J., Zhu, C., Liu, G., Lin, Y., Su, J., Yang, M., Yang, B., Ma, Y., et al. (2024) · Journal of Cellular Physiology · doi:10.1002/jcp.31291 · Cited by 9
“…p < 0.01; *** p < 0.001. primarily involves the use of bisphosphonates, Denosumab, Evenity, peptide hormones, and estrogen in postmenopausal women, as well as selective estrogen receptor modulators, all of which aim to reduce bone loss and resorption (Qaseem et al., 2017, 2023; Rider et al., 2018).”
InfluentialMartinez, J. P. D., Maraumont, T. A.-D., Sánchez, E. N., Cordero, L. M. C., & Yeh, E. J. (2025) · PLoS ONE · doi:10.1371/journal.pone.0299673 · Cited by 9
Elimination of intravenous alendronate by hemodialysis: A kinetic study
Iseri, K., Watanabe, M., Lee, X., Yamada, M., Ryu, K., Iyoda, M., Uchida, N., Sato, K., & Shibata, T. (2019) · Hemodialysis International · doi:10.1111/hdi.12773 · Cited by 9
Time to benefit and the long-term persistence of new users of oral bisphosphonates
Friesen, K. J., Bugden, S., & Falk, J. (2020) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-019-01069-x · Cited by 9
Long-Term Bioavailability of Single Doses of Intramuscular Vitamin D2
Xu, F., Dai, D., Sun, R., Liu, Z., Lin, X., Li, L., Xing, X., Wang, X., Li, C., & Xie, Z. (2020) · Endocrine Practice · doi:10.4158/ep-2020-0124 · Cited by 9
Estrogen and estrogen analogs for prevention and treatment of osteoporosis
Jiang, X., Randhawa, S. B., & Kagan, R. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813073-5.00073-3 · Cited by 9
Association of bone-related biomarkers with femoral neck bone strength
Xia, N., Cai, Y., Wang, W., Bao, C., Li, Y., Xie, Q., Xu, W., & Liu, D. (2022) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-022-05427-1 · Cited by 9
Zhao, D., Lin, X., Hu, J., Zhou, B., Zhang, Q., Wang, O., Jiang, Y., Xia, W., Xing, X., & Li, M. (2023) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-023-06397-8 · Cited by 9
Recommendations on deprescribing of bisphosphonates in osteoporosis guidelines: a systematic review
Jepsen, D. B., Bergen, E. S., Pan, J., van Poelgeest, E. P., Osman, A., Burghle, A., Ryg, J., Thompson, W., & Lundby, C. (2023) · European Geriatric Medicine · doi:10.1007/s41999-023-00820-y · Cited by 9
“[27] X – – – – – RACGP [50] X X X X X X Radominski et al.”
FRAX-derived intervention and assessment thresholds for osteoporosis in ten Middle Eastern countries
Naseri, A., Bakhshayeshkaram, M., Salehi, S., Heydari, S. T., Dabbaghmanesh, M. H., & Dabbaghmanesh, M. M. (2024) · Archives of Osteoporosis · doi:10.1007/s11657-024-01397-0 · Cited by 9
“Many guideline development agencies have expressed concerns about making treatment decisions without BMD measurements [22, 23].”
The Intersection of Medicine and Urology
Miner, M. M., Heidelbaugh, J. J., Paulos, M., Seftel, A. D., Jameson, J., & Kaplan, S. A. (2018) · Medical Clinics of North America · doi:10.1016/j.mcna.2017.11.002 · Cited by 9
The Economic Burden of Osteoporosis
Fogel, H. A., & Jenis, L. G. (2020) · Springer eBooks · doi:10.1007/978-3-030-33861-9_3 · Cited by 9
Abdalbary, M., Amin, A. M., Elaraby, A. R., & Hassan, A. (2025) · Osteoporosis International · doi:10.1007/s00198-025-07707-7 · Cited by 8
“Pre-dialysis CKD patients have double the fracture risk, which becomes worse in end-stage kidney disease (ESKD) [5, 6], and post-fracture mortality rates can soar to 64% within a year in dialysis patients [7].”
Quality appraisal of educational websites about osteoporosis and bone health
Lopez-Olivo, M. A., Bordes, J. D., Syed, M. N., Alemam, A., Dodeja, A., Abdel‐Wahab, N., & Suarez-Almazor, M. E. (2021) · Archives of Osteoporosis · doi:10.1007/s11657-021-00877-x · Cited by 8
Effects of kidney tonic herbs for primary osteoporosis: A systematic review and meta-analysis
Li, W., Ye, B., Huang, Z., Zhou, H., Feng, J., Chen, Q., Huang, H., Meng, S., Qie, F., & Shi, X. (2023) · Medicine · doi:10.1097/md.0000000000035061 · Cited by 8
Du, Y., Gao, X., Chen, J., Chen, X., Liu, H., He, W.-G., Liu, L., Jiang, Y., He, B., Deng, Z., et al. (2024) · Journal of Orthopaedic Translation · doi:10.1016/j.jot.2024.10.004 · Cited by 8
“…is a prevalent bone disease that is characterized by a reduction in bone mass, damage to bone microstructure, and an increase in bone fragility [1], and it is found in an estimated 200 million people worldwide, 50 % women and 20 % men aged over 50 years will suffer an osteoporotic fracture in…”
Effects of traditional Chinese medicine Zuo-Gui-Wan on gut microbiota in an osteoporotic mouse model
Li, J., HaomingYou, Hu, Y., Li, R., Ouyang, T., Qiang, R., Zhang, G., & Huang, Y. (2025) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-025-05504-w · Cited by 8
Fanelli, F., Guglielmi, G., Troiano, G., Rivara, F., Passeri, G., Prencipe, G., Zhurakivska, K., Guglielmi, R., & Calciolari, E. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14134462 · Cited by 8
“Early detection and intervention can effectively halt the progression of bone resorption and lower the chance of bone fractures [2].”
Documento de consenso de osteoporosis del varón
Varsavsky, M., Muñoz, M. R., Rubio, V. Á., Becerra, A., Martín, A. G., Diaz‐Guerra, G. M., Moreno, P. R., Gimeno, E. J., & Muñoz‐Torres, M. (2018) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2017.12.005 · Cited by 8
Leslie, W. D., Morin, S. N., Martineau, P., Bryanton, M., & Lix, L. M. (2019) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2019.03.006 · Cited by 8
Fuzzell, L. N., Richards, M. J., Fraenkel, L., Stark, S. L., & Politi, M. C. (2019) · Osteoporosis International · doi:10.1007/s00198-019-05008-4 · Cited by 8
Liu, J., Laster, A. J., Xu, X., Guo, H., Oates, M. K., & Gandra, S. R. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4439 · Cited by 8
“The current American College of Physicians (ACP) guidelines,((24)) which are widely used by primary care providers, highlight the use of antiresorptive agents and recommend not using anabolic agents as the initial therapy; high-risk patients were not specifically defined, and sequential therapy was not specifically ad…”
BackgroundOsteoporosis Care Gap After Hip Fracture – Worse With Low Healthcare Access and Quality
Galli, S. H., Weiss, D. M., Beck, A. P., & Scerpella, T. A. (2021) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2021.09.002 · Cited by 8
Zhao, S., Zhao, W., Du, D., Zhang, C., Zhao, T., Zheng, L., Jin, L., Gu, M., Xu, J., & Yang, Z. (2021) · Journal of Investigative Medicine · doi:10.1136/jim-2021-001961 · Cited by 8
Wang, Z., Wang, H., Zhuang, C., Chen, W., Hoang, T.-M., Li, J., & Lin, H. R. (2023) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-023-03792-8 · Cited by 8
“5 or lower at lumbar spine, femoral neck, or total hip, or previous history of OVCF, proximal femoral fracture, or other fragility fracture [10]; (3) 50 years old ≤ age ≤ 90 years old.”
BackgroundLi, R., Yuan, X., Chen, X., Ou, Y., & Chen, J. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1358592 · Cited by 8
Clinical Application of Teriparatide in Fracture Prevention: A Systematic Review
Chen, Y., Liu, R., Hettinghouse, A., Wang, S., Liu, G., & Liu, C.-J. (2019) · JBJS Reviews · doi:10.2106/jbjs.rvw.18.00052 · Cited by 8
Weaver, F. M., Le, B. K., Ray, C. E., Miskevics, S. A., González, B., & Carbone, L. D. (2019) · Journal of Spinal Cord Medicine · doi:10.1080/10790268.2019.1584259 · Cited by 8
Nesfatin-1 prevents negative changes in bone in conditions of developing osteopenia
Puzio, I., Tymicki, G., Pawłowska, M., Bieńko, M., & Radzki, R. P. (2019) · Annals of Agricultural and Environmental Medicine · doi:10.26444/aaem/105981 · Cited by 8
Lessons learned with Bone Health TeleECHO: making treatment decisions when guidelines conflict
Rothman, M. S., Olenginski, T. P., Stanciu, I., Krohn, K., & Lewiecki, E. M. (2019) · Osteoporosis International · doi:10.1007/s00198-019-05147-8 · Cited by 8
Yin, P., Shi, Q., Xiao, F., Zhao, B., Yu, W., Wu, K., & Peng, K. (2019) · Archives of Medical Science · doi:10.5114/aoms.2019.89979 · Cited by 8
“2 Arch Med Sci age-related bone loss disorder is based on blocking bone resorption using anti-resorptive therapeutic agents such as denosumab, bisphosphonates and zoledronic acid [1, 3].”
BackgroundUnderstanding Osteoporosis Screening Practices in Men: A Nationwide Physician Survey
Choksi, P. U., Gay, B. L., Reyes‐Gastelum, D., Haymart, M. R., & Papaleontiou, M. (2020) · Endocrine Practice · doi:10.4158/ep-2020-0123 · Cited by 8
Sakr, H. F., Ammar, B., Alkharusi, A., Al‐Lawati, I., Alkhateeb, M. A., & Elesawy, B. H. (2022) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-022-2895-2 · Cited by 8
“Nowadays, cl inical tr ials to prevent male osteoporosis and hip fracture in aged males is receiving much attention.((17)) Resveratrol (Res) is a polyphenolic phytoestrogen compound that is naturally found in the skin of red grapes, various other fruits, peanuts, and root extracts of the weed Polygonum cuspidatum.”
BackgroundWang, G., Chen, J., Ma, R., Xu, W., Yan, C., & Niu, C. (2018) · Oncology Letters · doi:10.3892/ol.2018.8804 · Cited by 8
Mahajan, A. N., Surti, N. I., Patel, P., Patel, A., Shah, D. A., & Patel, V. B. (2020) · Assay and Drug Development Technologies · doi:10.1089/adt.2020.990 · Cited by 8
Systemic Bone Loss and Periodontal Disease: An Updated Review of a Bidirectional Association
Alhumaidan, A. A., & Elakel, A. M. (2026) · Dentistry Journal · doi:10.3390/dj14010070 · Cited by 7
“Several lifestyle and systemic factors contribute to reduced BMD and osteoporosis, including alcohol consumption, tobacco use, diabetes, vitamin D deficiency, low body mass, and physical inactivity [2,3].”
Reis, T. G., Colletto, A. M. S. D., Silva, L. A. S., Koga, B. A. A., Sogayar, M. C., & Carreira, A. C. O. (2024) · Biomolecules · doi:10.3390/biom14030317 · Cited by 7
“…by bone mass loss and tissue microarchitecture degeneration, leading to an increased risk of fractures, being considered a serious public health problem [1,2] that affects approximately 200 million people worldwide, with a higher prevalence in post-menopausal women and elderly men [3].”
Weng, Z., Chen, X., Jiao, J., Fu, Z., Liu, Q., Xu, J., Zhang, H., Hou, Q., Wang, D., Li, J., et al. (2025) · Environment International · doi:10.1016/j.envint.2025.109442 · Cited by 7
Inappropriate vitamin D supplementation among multimorbid older patients: a multicountry analysis
Moutzouri, E., Beglinger, S., Feller, M., Eichenberger, A., Dalleur, O., Knol, W., Emmelot‐Vonk, M. H., O’Mahony, D., Boland, B. B., Aubert, C. E., et al. (2025) · BMC Geriatrics · doi:10.1186/s12877-025-06189-w · Cited by 8
Pharmacotherapy for Postmenopausal Osteoporosis
(2021) · JAMA · doi:10.1001/jama.2020.13841 · Cited by 7
Lian, Y., Zhu, H., Guo, X., Fan, Y., Xie, Z., Xu, J., & Shao, M. (2023) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-023-04031-w · Cited by 7
Russo, M., Liu, C., Liu, Y., Mahar, S., Rozental, T. D., & Harper, C. M. (2023) · The Journal Of Hand Surgery · doi:10.1016/j.jhsa.2023.07.006 · Cited by 7
Isaikin, A. I., Isaykina, О. Y., Идрисовна, Ш. Т., Shor, Y. M., & Kachanovsky, M. S. (2019) · Neurology neuropsychiatry Psychosomatics · doi:10.14412/2074-2711-2019-3-63-68 · Cited by 7
Niu, S., Chen, M., Yan, D., Liu, X., Guo, S., Ou, L., Fan, H., Lv, J., Wang, Q., Dong, W., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.893166 · Cited by 7
Zhou, Z., Huang, Z., Khan, H. M., Liu, Y., Zhao, Z., & Kong, Q. (2023) · Functional & Integrative Genomics · doi:10.1007/s10142-023-01116-x · Cited by 7
Association between urinary glyphosate exposure and bone mineral density in adults
Wang, Z., Zhang, H., Du, W., Hu, J., & Quan, R. (2023) · Medicine · doi:10.1097/md.0000000000036506 · Cited by 7
“[1,2] The prevalence of osteoporosis has been on the rise in recent years, leading to both physical and psychological harm to the affected individuals.”
BackgroundShim, J., Lin, T., Dashiell-Earp, C. N., Nechrebecki, M., & Leung, A. M. (2019) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-019-0085-8 · Cited by 7
Zhuang, H., Li, Y., Lin, J., Yao, X., Xie, Y., Wang, P., & Xu, H. Y. (2021) · Medical Science Monitor · doi:10.12659/msm.928637 · Cited by 7
“According to the Clinical Guidelines Committee of the American College of Physicians, bisphosphonates are the most commonly used drugs for the treatment of osteoporosis and significantly reduce the risk of fracture [1,2].”
Osteoporosis and low bone mineral density (osteopenia) in rural and remote Queensland
Macgregor, C., Meerkin, J. D., Alley, S., Vandelanotte, C., & Reaburn, P. R. J. (2018) · Australian Journal of Rural Health · doi:10.1111/ajr.12476 · Cited by 7
Effects of Estrogens and SERMs on Bone Metabolism: Clinical Aspects
Clarke, B. L. (2020) · Contemporary Endocrinology · doi:10.1007/978-3-319-69287-6_12 · Cited by 7
Editorial: Response to the American College of Physicians Osteoporosis Guideline, 2017 Update
Caplan, L., Hansen, K. E., & Saag, K. G. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40305 · Cited by 7
Fernandes, C., Campbell-Scherer, D. L., Lofters, A., Grunfeld, E., Aubrey‐Bassler, K., Cheung, H., Latko, K., Tink, W., Lewanczuk, R. Z., Shea-Budgell, M. A., et al. (2024) · BMC Family Practice · doi:10.1186/s12875-024-02388-3 · Cited by 6
Zoledronic acid in metastatic castrate-sensitive prostate cancer: A state-of-the-art review
Damaj, N., Najdi, T. A., Seif, S., Nakouzi, N. A., & Kattan, J. G. (2025) · Journal of bone oncology · doi:10.1016/j.jbo.2025.100667 · Cited by 6
Osteoporosis: Diagnosis and Management
Rawung, R., & Bagy, R. G. (2021) · e-CliniC · doi:10.35790/ecl.v9i2.32967 · Cited by 6
Liu, T., Yao, M., Zhao, Y., Zhao, S., Chen, R., & Yang, F. (2023) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-023-04264-9 · Cited by 6
“The main therapies for primary osteoporosis include physical exercise, nutritional supplements and anti-osteo-porosis drugs, and medication is the most recommended treatment [5, 6].”
BackgroundSahota, O., Narayanasamy, M. J., Bastounis, A., Paskins, Z., Bishop, S., Langley, T. E., Gittoes, N. J. L., Davis, S., Baily, A., Holmes, M., et al. (2024) · Health Technology Assessment · doi:10.3310/wypf0472 · Cited by 6
Ren, Z., He, L., Li, X., Yan, L., Ren, Z., & Liu, X. (2025) · Complementary Therapies in Clinical Practice · doi:10.1016/j.ctcp.2025.101956 · Cited by 6
Fang, Y., Wang, L., Xing, W., Wu, Q. F., Tong, Q., Yu, Y., Lv, X., Wang, B., & Wang, G. (2018) · European Geriatric Medicine · doi:10.1007/s41999-018-0027-5 · Cited by 6
Kamata, Y., & Minota, S. (2019) · Archives of Osteoporosis · doi:10.1007/s11657-019-0637-7 · Cited by 6
Minodronate in the treatment of osteoporosis: A systematic review and meta-analysis
Liu, Q., Chen, D., Ye, Z., Jin, Z., Ma, T., & Huang, X. (2020) · Medicine · doi:10.1097/md.0000000000022542 · Cited by 6
Metadata
- Authors
- Qaseem, A., Forciea, M. A., McLean, R. M., Denberg, T. D., & for the Clinical Guidelines Committee of the American College of Physicians*
- Affiliations
- Yale University (US)
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2017-06-06
- Volume
- 166
- Issue
- 11
- Pages
- 818-839
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2614075773
- Cited by
- 676
- References
- 368
- Citations by year
- 2026: 33 · 2025: 53 · 2024: 65 · 2023: 85 · 2022: 82 · 2021: 81 · 2020: 95 · 2019: 75 · 2018: 70 · 2017: 35
- FWCI
- 83.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- osteoporosis, osteopenia, fracture prevention, pharmacotherapy, bisphosphonates, denosumab, zoledronic acid, risedronate, alendronate, hormone replacement therapy, raloxifene, calcium and vitamin D supplementation, treatment duration, hip fracture
- MeSH terms
- Denosumab, Bone Diseases, Metabolic, Calcium, Dietary, Diphosphonates, Female, Humans, Male, Osteoporosis, Risk Factors, Vitamin D, Exercise, Osteoporosis, Postmenopausal, Estrogen Replacement Therapy, Teriparatide, Raloxifene Hydrochloride, Fractures, Bone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.